$8.91 earnings per share for the current year. Rodman & Renshaw Reaffirms Buy Rating for Valeant Pharmaceuticals Intl Inc (VRX)
Posted by mitch on Mar 25th, 2016
Rodman & Renshaw reaffirmed their buy rating on shares of Valeant Pharmaceuticals Intl Inc (NYSE:VRX) in a research report sent to investors on Tuesday morning, MarketBeat reports.
A number of institutional investors have recently added to or reduced their stakes in VRX. Deltec Asset Management LLC purchased a new position in Valeant Pharmaceuticals Intl during the fourth quarter valued at about $610,000. Breton Hill Capital Ltd. raised its position in Valeant Pharmaceuticals Intl by 73.4% in the fourth quarter. Breton Hill Capital Ltd. now owns 10,122 shares of the specialty pharmaceutical company’s stock valued at $1,029,000 after buying an additional 4,285 shares in the last quarter. Oppenheimer & Co. Inc. raised its position in Valeant Pharmaceuticals Intl by 51.2% in the fourth quarter. Oppenheimer & Co. Inc. now owns 10,455 shares of the specialty pharmaceutical company’s stock valued at $1,062,000 after buying an additional 3,541 shares in the last quarter. RiverPark Advisors LLC raised its position in Valeant Pharmaceuticals Intl by 21.3% in the fourth quarter. RiverPark Advisors LLC now owns 12,495 shares of the specialty pharmaceutical company’s stock valued at $1,270,000 after buying an additional 2,195 shares in the last quarter. Finally, Deere & Co. raised its position in Valeant Pharmaceuticals Intl by 121.1% in the fourth quarter. Deere & Co. now owns 15,011 shares of the specialty pharmaceutical company’s stock valued at $1,526,000 after buying an additional 8,222 shares in the last quarter.
A number of other brokerages have also recently commented on VRX. Mizuho reaffirmed a neutral rating and issued a $112.00 target price (down from $130.00) on shares of Valeant Pharmaceuticals Intl in a report on Sunday, January 3rd. Barclays cut Valeant Pharmaceuticals Intl from an overweight rating to an equal weight rating and decreased their target price for the stock from $135.00 to $34.00 in a report on Monday. Vetr raised Valeant Pharmaceuticals Intl from a buy rating to a strong-buy rating and set a $122.73 target price on the stock in a report on Tuesday, December 29th. TD Securities cut Valeant Pharmaceuticals Intl from a buy rating to a hold rating and decreased their target price for the stock from $155.00 to $110.00 in a report on Monday, February 29th. Finally, Jefferies Group reaffirmed a buy rating and issued a $106.00 target price (down from $172.00) on shares of Valeant Pharmaceuticals Intl in a report on Monday, February 29th. Six equities research analysts have rated the stock with a sell rating, fifteen have issued a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company. Valeant Pharmaceuticals Intl presently has an average rating of Hold and an average target price of $91.04.
Valeant Pharmaceuticals Intl (NYSE:VRX) opened at 31.09 on Tuesday. The stock’s 50 day moving average is $67.76 and its 200-day moving average is $110.59. Valeant Pharmaceuticals Intl has a 52-week low of $25.99 and a 52-week high of $263.81. The firm has a market capitalization of $10.67 billion and a PE ratio of 17.86.
Valeant Pharmaceuticals Intl (NYSE:VRX) last released its quarterly earnings results on Tuesday, March 15th. The specialty pharmaceutical company reported $2.50 earnings per share for the quarter, missing the consensus estimate of $2.61 by $0.11. During the same quarter last year, the firm earned $2.58 earnings per share. The firm earned $2.80 billion during the quarter, compared to analysts’ expectations of $2.75 billion. Valeant Pharmaceuticals Intl’s revenue for the quarter was up 22.3% on a year-over-year basis. Equities analysts expect that Valeant Pharmaceuticals Intl will post $8.91 earnings per share for the current year.